Calcitonin physiology, saved by a lysophospholipid

Journal of Bone and Mineral Research

Volumn 30, Issue 2, 2015, Pages 212-215

  Martin, T John ^a   Sims, Natalie A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR; CALCIUM; LYSOPHOSPHOLIPID; PARATHYROID HORMONE; PROCALCITONIN; SPHINGOSINE;

BONE MASS; BONE REMODELING; CALCIUM HOMEOSTASIS; CELL COMMUNICATION; HEMIZYGOTE; HYPERCALCEMIA; MORPHOMETRICS; NONHUMAN; NOTE; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PHYSIOLOGY; TRABECULAR BONE; ANALOGS AND DERIVATIVES; ANIMAL; BONE DEVELOPMENT; CYTOLOGY; FEMALE; METABOLISM;

ANIMALS; CALCITONIN; FEMALE; LYSOPHOSPHOLIPIDS; OSTEOCLASTS; OSTEOGENESIS; SPHINGOSINE;

EID: 84921717498     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2449     Document Type: Note

References (48)

1. Keller J, Catala-Lehnen P, Huebner AK, et al. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat Commun. 2014;5:5215 doi: 10.1038/ncomms6215
2. Copp DH, Cameron EC, Cheney BA, Davidson AG, Henze KG. Evidence for calcitonin - a new hormone from the parathyroid that lowers blood calcium. Endocrinology. 1962;70:638-649.
3. Macintyre I, Foster GV, Kumar MA. Calcium metabolism. Calcitonin. Proc R Soc Med. 1964;57:865-866.
4. Hirsch PF, Voelkel EF, Munson PL. Thyrocalcitonin: hypocalcemic hypophosphatemic principle of the thyroid gland. Science. 1964;146:412-413.
5. Friedman J, Raisz LG. Thyrocalcitonin: inhibitor of bone resorption in tissue culture. Science. 1965;150:(702):1465-1467.
6. Martin TJ, Robinson CJ, MacIntyre I. The mode of action of thyrocalcitonin. Lancet. 1966;1:(7443):900-902.
7. Johnston CC Jr, Deiss WP Jr. An inhibitory effect of thyrocalcitonin on calcium release in vivo and on bone metabolism in vitro. Endocrinology. 1966;78:(6):1139-1143.
8. Robinson CJ, Martin TJ, Matthews EW, MacIntyre I. Mode of action of thyrocalcitonin. J Endocrinol. 1967;39:(1):71-79.
9. Nicholson GC, Moseley JM, Sexton PM, Mendelsohn FA, Martin TJ. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterization. J Clin Invest. 1986;78:(2):355-360.
10. Chambers TJ, Athanasou NA, Fuller K. Effect of parathyroid hormone and calcitonin on the cytoplasmic spreading of isolated osteoclasts. J Endocrinol. 1984;102:(3):281-286.
11. Martin TJ, Findlay DM, Sexton PM. Calcitonin. In: Jamieson LJDJL, editor., Endocrinology. New York: Elsevier. 2010; 1:pp 1419-1434.
12. Hirsch PF, Baruch H. Is calcitonin an important physiological substance? Endocrine. 2003;21:(3):201-208.
13. Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest. 2002;110:(12):1849-1857.
14. Schinke T, Liese S, Priemel M, et al. Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res. 2004;19:(12):2049-2056.
15. Huebner AK, Schinke T, Priemel M, et al. Calcitonin deficiency in mice progressively results in high bone turnover. J Bone Miner Res. 2006;21:(12):1924-1934.
16. Dacquin R, Davey RA, Laplace C, et al. Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. J Cell Biol. 2004;164:(4):509-514.
17. Davey RA, Turner A, McManus JF, et al. The calcitonin receptor plays a physiological role to protect against hypercalcemia in mice. J Bone Miner Res. 2008;23:(8):1182-1193.
18. Naot D, Cornish J. The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. Bone. 2008;43:(5):813-818.
19. Gooi JH, Chia LY, Walsh NC, et al. Decline in calcitonin receptor expression in osteocytes with age. J Endocrinol. 2014;221:(2):181-191.
20. Gooi JH, Pompolo S, Karsdal MA, et al. Calcitonin impairs the anabolic effect of PTH in young rats and stimulates expression of sclerostin by osteocytes. Bone. 2010;46:(6):1486-1497.
21. Paic F, Igwe JC, Nori R, et al. Identification of differentially expressed genes between osteoblasts and osteocytes. Bone. 2009;45:(4):682-692.
22. Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH, Jr, Becker KL. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med. 2008;36:(5):1637-1640.
23. Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86:(1):396-404.
24. Nylen ES, Whang KT, Snider RH, Jr, Steinwald PM, White JC, Becker KL. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med. 1998;26:(6):1001-1006.
25. Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling the chemokine sphingosine-1-phosphate. Proc Natl Acad Sci USA. 2008;105:(52):20764-20769.
26. Ryu J, Kim HJ, Chang EJ, Huang H, Banno Y, Kim HH. Sphingosine 1-phosphate as a regulator of osteoclast differentiation osteoclast-osteoblast coupling. Embo J. 2006;25:(24):5840-5851.
27. Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123:(2):666-681.
28. Sims NA, Martin TJ. Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit. Bonekey Rep. 2014;3:481.
29. Martin TJ. Coupling factors: how many candidates can there be? J Bone Miner Res. 2014;29:(7):1519-1521.
30. Bassett JH, Gogakos A, White JK, et al. Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genet. 2012;8:(8):e1002858.
31. Fukuhara S, Simmons S, Kawamura S, et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest. 2012;122:(4):1416-1426.
32. Brunkhorst R, Vutukuri R, Pfeilschifter W. Fingolimod for the treatment of neurological diseases - state of play and future perspectives. Front Cell Neurosci. 2014;8:283.
33. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427:(6972):355-360.
34. Brizuela L, Martin C, Jeannot P, et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol Oncol. 2014;8:(7):1181-1195.
35. Xiong Y, Hla T. S1P control of endothelial integrity. Curr Top Microbiol Immunol. 2014;378:85-105.
36. Im DS. Linking Chinese medicine and G-protein-coupled receptors. Trends Pharmacol Sci. 2003;24:(1):2-4.
37. Ontaneda D, Cohen JA. Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Exp Rev Clin Pharmacol. 2011;4:(5):567-570.
38. Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277:(24):21453-21457.
39. Sato C, Iwasaki T, Kitano S, Tsunemi S, Sano H. Sphingosine 1-phosphate receptor activation enhances BMP-2-induced osteoblast differentiation. Biochem Biophys Res Commun. 2012;423:(1):200-205.
40. Petrie Aronin CE, Shin SJ, Naden KB, et al. The enhancement of bone allograft incorporation by the local delivery of the sphingosine 1-phosphate receptor targeted drug FTY720. Biomaterials. 2010;31:(25):6417-6424.
41. Petrie Aronin CE, Sefcik LS, Tholpady SS, et al. FTY720 promotes local microvascular network formation, regeneration of cranial bone defects. Tissue Eng Part A. 2010;16:(6):1801-1809.
42. Heilmann A, Schinke T, Bindl R, et al. Systemic treatment with the sphingosine-1-phosphate analog FTY720 does not improve fracture healing in mice. J Orthop Res. 2013;31:(11):1845-1850.
43. Ishii M, Egen JG, Klauschen F, et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature. 2009;458:(7237):524-528.
44. Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J Exp Med. 2010;207:(13):2793-2798.
45. McCauley LK, Martin TJ. Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res. 2012;27:(6):1231-1239.
46. Basuyau JP, Mallet E, Leroy M, Brunelle P. Reference intervals for serum calcitonin in men, women, and children. Clin Chem. 2004;50:(10):1828-1830.
47. Sims N, Quinn J, Martin T. Coupling between immune and bone cells. 2nd ed. London: Academic Press in press.
48. Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med. 2005;11:(2):76-81.